



October 25, 2019

BSE Limited
P. J. Towers
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E),
Mumbai - 400 051

Dear Sirs,

Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regarding Slump Sale of India Branded Pharmaceuticals Business to a wholly owned indirect subsidiary

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the disclosure pertaining to sale of India Branded Pharmaceuticals Business of the Company to Jubilant Generics Limited, a wholly-owned indirect subsidiary of the Company. The same has been approved by the Board at its meeting held on October 25, 2019. Relevant details are given in **Annexure-A**.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624

Sr. No.	Particulars	Details																
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	<p><u>Details of India Branded Pharmaceuticals Business ('IBP Business') for FY 2018-19:</u></p> <p style="text-align: right;">(Rs. Crore)</p> <table border="1"> <thead> <tr> <th>Sr. No.</th> <th>Particulars</th> <th>Turnover</th> <th>Net worth</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Jubilant Life Sciences Limited</td> <td>3,438.61</td> <td>2,340.31</td> </tr> <tr> <td>2</td> <td>IBP Business</td> <td>24.75</td> <td>-0.69</td> </tr> <tr> <td>3</td> <td>Percentage</td> <td>0.7%</td> <td>0.0%</td> </tr> </tbody> </table>	Sr. No.	Particulars	Turnover	Net worth	1	Jubilant Life Sciences Limited	3,438.61	2,340.31	2	IBP Business	24.75	-0.69	3	Percentage	0.7%	0.0%
Sr. No.	Particulars	Turnover	Net worth															
1	Jubilant Life Sciences Limited	3,438.61	2,340.31															
2	IBP Business	24.75	-0.69															
3	Percentage	0.7%	0.0%															
2.	Date on which the agreement for sale has been entered into	On or before January 1, 2020																
3.	The expected date of completion of sale/disposal	Sale of IBP Business to Jubilant Generics Limited ('JGL'), a wholly-owned indirect subsidiary of the Company, would be effective on or before January 1, 2020																
4.	Consideration received from such sale/disposal	Rs. 128.5 Crores, payable in cash or as mutually agreed, in one or more installments.																
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	The buyer is JGL, a wholly-owned indirect subsidiary of the Company.																
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms' length"	<p>The transaction has been undertaken between the Company and its wholly-owned indirect subsidiary. Hence, the transaction is a Related Party Transaction.</p> <p>The consideration has been arrived at on the basis of the Valuation Report of M/s Incwert Advisory Private Limited, Independent Registered Valuers. The transaction is, therefore, on arms' length basis.</p>																

Sr. No.	Particulars	Details
7.	Area of business of the entity(ies)	<p><u>Jubilant Life Sciences Limited</u></p> <p>Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses.</p> <p><u>Jubilant Generics Limited</u></p> <p>JGL is engaged in the business of manufacturing of Active Pharmaceutical Ingredients and Dosage Formulations.</p>
8.	Rationale for slump sale	<p>The sale of IBP Business would <i>inter alia</i> result in the following benefits for the Company:</p> <ol style="list-style-type: none"> 1. Integration of IBP business with Global Generics Business of JGL leading to operational synergies 2. To avoid any perceived conflict of businesses carried on by Jubilant Pharma Limited, Singapore (JPL Singapore) and Jubilant Life Sciences Limited (JLL India), its shareholding entity 3. Fits naturally to the R&D & Manufacturing base of JGL business
9.	Brief details of change in shareholding pattern (if any) of the listed entity	There would be no change in the shareholding pattern of the Company consequent to sale of IBP Business.

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624